Diabetes is one of the fatal diseases that play a vital role in the growth of other diseases in the human body. Controlling and curing diabetes in its early stages is the most significant technique to avoid its effects of diabetes. However, lack of awareness and expensive clinical tests are the primary reasons to skip clinical diagnosis and take preventive methods in lower-income countries like Bangladesh, Pakistan, and India. From this perspective, the study aims to build an automated machine learning (ML) model, which will predict diabetes at an early stage using socio-demographic characteristics rather than clinical attributes. Because clinical features are not always known to all people from lower-income countries. To find the best fit supervised ML classifier of the model, we applied six classification algorithms and found that RF outperformed with an accuracy of 99.36%. In addition, the most significant risk factors were found based on the SHAP value by all the applied classifiers. The study reveals that polyuria, polydipsia, and delayed healing are the most significant risk factors for growing diabetes. The findings indicate that the proposed model is highly capable of predicting diabetes in the early stages.

Rare ginsenoside compound K (CK), is an intestinal microbial metabolite with a low natural abundance that is primarily produced by physicochemical processing, side chain modification, or metabolic transformation in the gut. Moreover, CK exhibits potent biological activity compared to primary ginsenosides, which has raised concerns in the field of ginseng research and development as well as ginsenosides-related dietary supplements and natural products. Ginsenosides Rb1, Rb2, and Rc are generally used as a substrate to generate CK via several bio-conversion processes. Current research shows that CK has a wide range of pharmacological actions including boosting osteogenesis, lipid and glucose metabolism, lipid oxidation, insulin resistance, anti-inflammatory, and anti-apoptosis properties. Further research on the bioavailability and toxicology of CK can advance its medicinal application. The purpose of this review is to lay the groundwork for future clinical studies and the development of CK as a therapy for metabolic disorders. Furthermore, the toxicology and pharmacology of CK are investigated as well in this review. The findings indicate that CK primarily modulates signal-ing pathways associated with AMPK, SIRT1, PPARs, WNTs, and NF-kB. It also demonstrates a positive therapeutic effect of CK on nonalcoholic fatty liver disease, obesity, hyperlipidemia, diabetes, and its complications, as well as osteoporosis. Additionally, the analogues of CK showed more bioavailability, less toxicity, and more efficacy against disease states. Enhancing bioavailability and regulating hazardous variables are crucial for its use in clinical trials.